Hong-xing Q. Pan
Jiangsu Road
Nanjing, 210009, China
Nanjing, 210009, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Post-Marketing Safety of mRNA Vaccines: A Real-World Study Integrating Literature Case Reports and Vaccine Adverse Event Reporting System.
Journal: Vaccines
Published: April 15, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: November 28, 2025
Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2 Years and Older in China.
Journal: Infectious diseases and therapy
Published: November 24, 2025
Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: April 11, 2025
Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial.
Journal: Nature communications
Published: April 03, 2025
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3-17 years.
Journal: NPJ vaccines
Published: July 09, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
Journal: The Lancet. Infectious diseases
Published: December 03, 2023
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.
Journal: Expert review of vaccines
Published: July 11, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Journal: The Lancet regional health. Western Pacific
Published: April 12, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Journal: The Lancet. Infectious diseases
Published: March 14, 2023
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: February 06, 2023
Last Updated: 09/26/2026